Key result
Oral ibuprofen appears to be an effective and inexpensive alternative to intravenous prostaglandin synthesis inhibitors for managing patent ductus arteriosus in infants.
Why the study?
Does oral ibuprofen provide an effective alternative to intravenous prostaglandin synthesis inhibitors for ductal closure in very low birth weight infants with patent ductus arteriosus?
Does oral ibuprofen provide an effective alternative to intravenous prostaglandin synthesis inhibitors for ductal closure in very low birth weight infants with patent ductus arteriosus?
Answers are grounded in this paper and cite their sources.
Oral ibuprofen may be an effective and cost-efficient alternative to intravenous medications for managing patent ductus arteriosus in very low birth weight infants.
Patent ductus arteriosus is a common problem in very low birth weight infants. Prostaglandin synthesis inhibitors such as indomethacin and ibuprofen are widely used preferred medications for ductal closure but the question of which one should be preferred is controversial. There are some studies in the literature comparing their pharmacokinetics, efficacy, side effects and long-term outcomes. In this review we aimed to focus on prostaglandin synthesis inhibitors with their pharmacodynamic and pharmacokinetic in relation to oral and intravenous forms. Oral ibuprofen seems to be an effective and cheap alternative to the intravenous forms. Studies in extremely low birth weight infants that also evaluate the neurodevelopment will clarify its use.
No takes yet. Share an insight, caveat, or question.
Demırel et al. (2012) conducted a review in Patent ductus arteriosus. Oral ibuprofen vs. Intravenous medications (indomethacin and ibuprofen) was evaluated. Oral ibuprofen appears to be an effective and inexpensive alternative to intravenous prostaglandin synthesis inhibitors for managing patent ductus arteriosus in infants.
Synapse has enriched 10 related papers. Consider them for comparative context: